Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections

To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Tober-Lau, Pinkus, Gruell, Henning, Vanshylla, Kanika, Koch, Willi M., Hillus, David, Schommers, Philipp, Suárez, Isabelle, Suttorp, Norbert, Sander, Leif Erik, Klein, Florian, Kurth, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045428/
https://www.ncbi.nlm.nih.gov/pubmed/35259088
http://dx.doi.org/10.3201/eid2805.220271
_version_ 1784695314587844608
author Tober-Lau, Pinkus
Gruell, Henning
Vanshylla, Kanika
Koch, Willi M.
Hillus, David
Schommers, Philipp
Suárez, Isabelle
Suttorp, Norbert
Sander, Leif Erik
Klein, Florian
Kurth, Florian
author_facet Tober-Lau, Pinkus
Gruell, Henning
Vanshylla, Kanika
Koch, Willi M.
Hillus, David
Schommers, Philipp
Suárez, Isabelle
Suttorp, Norbert
Sander, Leif Erik
Klein, Florian
Kurth, Florian
author_sort Tober-Lau, Pinkus
collection PubMed
description To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.
format Online
Article
Text
id pubmed-9045428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-90454282022-05-07 Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections Tober-Lau, Pinkus Gruell, Henning Vanshylla, Kanika Koch, Willi M. Hillus, David Schommers, Philipp Suárez, Isabelle Suttorp, Norbert Sander, Leif Erik Klein, Florian Kurth, Florian Emerg Infect Dis Research Letter To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers. Centers for Disease Control and Prevention 2022-05 /pmc/articles/PMC9045428/ /pubmed/35259088 http://dx.doi.org/10.3201/eid2805.220271 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Tober-Lau, Pinkus
Gruell, Henning
Vanshylla, Kanika
Koch, Willi M.
Hillus, David
Schommers, Philipp
Suárez, Isabelle
Suttorp, Norbert
Sander, Leif Erik
Klein, Florian
Kurth, Florian
Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
title Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
title_full Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
title_fullStr Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
title_full_unstemmed Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
title_short Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
title_sort cross-variant neutralizing serum activity after sars-cov-2 breakthrough infections
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045428/
https://www.ncbi.nlm.nih.gov/pubmed/35259088
http://dx.doi.org/10.3201/eid2805.220271
work_keys_str_mv AT toberlaupinkus crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT gruellhenning crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT vanshyllakanika crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT kochwillim crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT hillusdavid crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT schommersphilipp crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT suarezisabelle crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT suttorpnorbert crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT sanderleiferik crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT kleinflorian crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections
AT kurthflorian crossvariantneutralizingserumactivityaftersarscov2breakthroughinfections

Ejemplares similares